Helga joined Brandon Capital Partners in 2018.
Before joining Helga was part of the team that developed a novel treatment for respiratory disease at the Telethon Kids Institute in Perth which subsequently became Respirion Pharmaceuticals. Previously Helga project managed the development of anti-infective medical devices for CamStent, Cambridge, UK. Helga undertook postdoctoral training in bacterial genetics at the University of Cambridge and Imperial College London.
Helga has both a Bachelor and Masters of Science in Chemical Engineering and Biotechnology from the Technical University of Denmark and a PhD in Microbiology from the University of Cambridge.